Havemeyer Place LP purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 12,053 shares of the medical device company’s stock, valued at approximately $800,000.
A number of other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of DexCom by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after acquiring an additional 1,133,638 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of DexCom by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock worth $727,842,000 after acquiring an additional 42,411 shares during the last quarter. Norges Bank acquired a new position in shares of DexCom in the 4th quarter worth $483,356,000. CIBC Private Wealth Group LLC grew its holdings in shares of DexCom by 374.3% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock worth $195,666,000 after acquiring an additional 2,294,709 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in shares of DexCom by 4.7% in the third quarter. Legal & General Group Plc now owns 2,635,700 shares of the medical device company’s stock worth $177,356,000 after buying an additional 117,493 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other DexCom news, EVP Jon Coleman sold 4,911 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $74.13, for a total value of $364,052.43. Following the completion of the sale, the executive vice president owned 95,450 shares of the company’s stock, valued at $7,075,708.50. The trade was a 4.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $59.91, for a total value of $101,847.00. Following the completion of the sale, the executive vice president directly owned 109,504 shares of the company’s stock, valued at $6,560,384.64. This represents a 1.53% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 42,694 shares of company stock worth $3,029,267 over the last ninety days. 0.28% of the stock is currently owned by corporate insiders.
DexCom Price Performance
DexCom (NASDAQ:DXCM – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the firm earned $0.32 earnings per share. The business’s quarterly revenue was up 15.0% compared to the same quarter last year. On average, equities research analysts predict that DexCom, Inc. will post 2.57 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
DXCM has been the subject of several recent analyst reports. Barclays reaffirmed an “underweight” rating and issued a $64.00 target price (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. TD Cowen decreased their target price on DexCom from $84.00 to $75.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Stifel Nicolaus set a $90.00 price objective on DexCom and gave the company a “buy” rating in a research report on Friday. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Finally, Benchmark initiated coverage on DexCom in a research report on Monday, May 11th. They set a “buy” rating and a $77.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $83.04.
Read Our Latest Report on DXCM
DexCom Profile
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
Featured Articles
- Five stocks we like better than DexCom
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
